- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Bradley Monk on Response to PARP Inhibitors in Ovarian Cancer
Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, discusses the ovarian cancer patients most likely to respond well to PARP inhibition.
Bradley Monk, MD, FACOG, FACS, professor at the University of Arizona and Creighton University in Phoenix and clinician at Arizona Oncology, discusses the ovarian cancer patients most likely to respond well to PARP inhibition.
Transcript
In your experience, who are the patients who fare best with PARP inhibitors for ovarian cancer?
The first randomized trials to show efficacy of PARP inhibitors were these 3 maintenance treatments in recurrent ovarian cancer, and olaparib has 2 studies, Study 19 and SOLO2; niraparib of has one, NOVA; and then rucaparib has 1, ARIEL3. And so you can now use PARP inhibitors in treatment in recurrent ovarian cancer based on level 1 randomized trial data, if the patient responds to platinum, across all biomarker subgroups, because response to platinum in the recurrent setting is the biomarker. So again, if you treat a patient in platinum-sensitive relapse with carboplatin-paclitaxel, or carboplatin-liposomal doxorubicin, or even carboplatin-gemcitabine, if she responds, you can keep her in response with either olaparib, rucaparib, or niraparib without sort of ruining the patient experience. All of those studies have no decrement in patient reported outcomes, and no new safety signals identified.
Nomogram Predicts Overall Survival in Patients With Ovarian Cancer, Liver Metastases
January 9th 2025Researchers developed and validated a nomogram to predict 1-, 2-, and 3-year overall survival (OS) in patients with ovarian cancer and liver metastases (OCLM), outperforming an external model in stability and accuracy.
Read More
Global Trends in Ovarian Cancer Incidence Highlight Regional, Histological Variations
January 7th 2025Between 1988 and 2017, there were significant global variations and trends in ovarian cancer incidence and its subtypes, influenced by genetic, reproductive, and socioeconomic factors.
Read More
Top 5 Most-Read Ovarian Cancer Content of 2024
December 29th 2024The top 5 ovarian cancer articles of 2024 covered topics such as the impact of air pollution on ovarian cancer risk, treatment strategies for patients with liver metastases, and the benefits of early diagnosis through symptom-triggered testing.
Read More
Exercise May Benefit Chemotherapy-Induced Peripheral Neuropathy in Patients With Ovarian Cancer
December 23rd 2024Exercise interventions may help manage chemotherapy-induced peripheral neuropathy (CIPN) in patients with ovarian cancer through improved physical activity and muscle function, but evidence remains limited.
Read More
Addressing Ovarian Cancer Outcome Disparities With Cultural Understanding, Disaggregated Research
December 16th 2024In the final part of our interview, Alice W. Lee, PhD, MPH, highlights the importance of addressing ovarian cancer care disparities and beyond by understanding cultural and behavioral factors and adopting a more disaggregated approach to research.
Read More
